GHENT, BELGIUM--(Marketwire - January 22, 2012) - Ablynx [Euronext Brussels: ABLX] issued the
following statement today. On Friday January 20(th) at 16.30 C.E.T., De
Belgian newspaper, published online what was alleged to be a summary of a
article relating to Ablynx, scheduled to appear in print on
January 21(st). The online summary contained a number of negative
quotations apparently resulting from an interview with Dr Edwin Moses,
and CEO of Ablynx. These statements and quotations were poorly
simply not reflective of the interview that took place. Ablynx's stock
fell almost 14% in about an hour and over 400,000 shares were traded in
two to three times the normal volume. A number of investors that
Ablynx directly were clearly completely misled by the summary
assumed that disappointing news had been announced. In fact, no
information had been provided during the interview with De Tijd.
On Saturday January 21(st), the full printed article appeared in De Tijd.
are significant errors in many of the quotations and statements in this
article but it is more representative of the actual interview than the
Dr Moses commented: "We have asked De Tijd to remove the online summary
their website which they have done. The full article is now available
To assist investors, we are posting on the Ablynx website our
translation of the De Tijd article which we have edited extensively to
what we believe are material factual errors in statements or quotations.
has developed into one of Europe's leading public biotechnology companies
is vital for us and all our stakeholders that the media report our
properly and accurately."
Ablynx is a biopharmaceutical company engaged in the discovery and
of Nanobodies®, a novel class of therapeutic proteins based on
antibody fragments, for a range of serious and life-threatening human
including inflammation, haematology, oncology and pulmonary disease.
Company has over 25 programmes in the pipeline and seven Nanobodies in
development. Ablynx has ongoing research collaborations and
partnerships with major pharmaceutical companies, including
Ingelheim, Merck Serono, Novartis, and has had a collaboration with
Company is headquartered in Ghent, Belgium and currently employs over
people. More information can be found on www.ablynx.com.
Complete version of the press release:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE